title: Humoral immune response to proteins of human cytomegalovirus latency-associated transcripts.
abstract: Latent human cytomegalovirus (CMV) infection of hematopoietic progenitor cells is associated with the presence of latency-associated transcripts that may express 6 proteins larger than 44 amino acids in size (open reading frame [ORF] 55, ORF45, ORF94, ORF59, ORF154, ORF152/UL124). The serologic response to these proteins was evaluated in healthy seropositive individuals as well as in individuals undergoing active CMV infection. Individual recombinant GST-fusion proteins, prepared from bacteria, were found by enzyme-linked immunosorbent assay to be recognized by between 8% and 44% long-term healthy seropositive individuals, with ORF94 and ORF55 being the most broadly and significantly recognized. Although nearly all of serum samples (85%) recognized at least 1 of these proteins, none reacted with all 6. Patterns of antibody prevalence to these proteins in long-term seropositive individuals were similar to many antigens expressed during productive replication (IE1, ppUL57, ppUL83/pp65), but none were broadly detected by a majority of individuals, a characteristic of only a few productive-phase antigens, including ppUL44/ICP36 and ppUL32/pp150. Consistent with prevalence in long-term seropositive individuals, commercial preparations of pooled human gamma globulin were also found to recognize latency-associated proteins. Serologic reactivity to latency-associated proteins was slow to develop following primary infection, in a pattern distinct from any of the characterized replication-phase proteins tested here, and was boosted late after secondary infection or reactivation in solid-organ transplant recipients without showing a correlation with viremia or disease. These results provide evidence that proteins expressed from the latent region during natural infection exhibit immunogenicity comparable with most other characterized viral antigens, although the narrow response to individual latency-associated proteins likely precludes their use in serologic assays to investigate clinical correlates or outcome in transplant recipients.
authors.affiliation: Department of Clinical and Experimental Medicine, University of Bologna, Italy.
authors.forename: M P
authors.initials: MP
authors.lastname: Landini
authors.forename: T
authors.initials: T
authors.lastname: Lazzarotto
authors.forename: J
authors.initials: J
authors.lastname: Xu
authors.forename: A P
authors.initials: AP
authors.lastname: Geballe
authors.forename: E S
authors.initials: ES
authors.lastname: Mocarski
mesh_terms: D000914:Antibodies, Viral / Q000096:biosynthesis*; D001483:Base Sequence; D003587:Cytomegalovirus / Q000235:genetics* / Q000276:immunology* / Q000472:pathogenicity; D003586:Cytomegalovirus Infections / Q000276:immunology / Q000635:transmission; D017931:DNA Primers / Q000235:genetics; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D016366:Open Reading Frames; D014760:Viral Fusion Proteins / Q000235:genetics / Q000276:immunology; D005719:gamma-Globulins / Q000276:immunology
chemical_list: D000914:Antibodies, Viral; D017931:DNA Primers; D014760:Viral Fusion Proteins; D005719:gamma-Globulins